Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Close this search box.


Biologics is one of Syngene’s  core service offerings comprising integrated services across the drug discovery, development and manufacturing continuum. We are committed to incrementally adding new layers of expertise to drive continued innovation. Solving our partners’ complex research and manufacturing problems, has been the hallmark of our success, and sustainable long-term relationships.

Meeting the capacity needs of the biologics Industry

In this video, our VP of manufacturing, Alex Del Priore discusses the implications of the rapidly increasing demand for biologics development and production, how the biologics industry is responding to that demand, and the important factors to consider when selecting a CDMO partner for biologics manufacturing.


Our Biologics Discovery services span the entire spectrum of early-stage research from target identification to delivery of drug candidates for further development. Our services cover recombinant DNA engineering, cell line development, hybridoma technology, next-generation sequencing, and protein sciences (purification & crystallography). Additionally, we also support integrated drug discovery for biologics with SynVent – Syngene’s platform for fully integrated therapeutic discovery and development.

Molecular Biology
Protein Sciences
Cell Line Development & Analysis
Antibody Generation

Development & Manufacturing

We work with diverse biological entities like monoclonal antibodies, bispecifics, antibody fragments, recombinant proteins, glycoproteins, Pegylated proteins, subunit protein vaccines, mRNA, microbial (E. coli and Pichia), microbiome live biotherapeutic product (LBP) and multimeric protein complexes.
We are a fully integrated custom biomanufacturer. Our biologics manufacturing facility caters to multi-product production campaigns simultaneously, based on single-use technology platform.

Development And Manufacturing Services
Analytical Characterization & Quality control
Viral Testing & Clearence
Bioanalytical Laboratory Services

CEO and MD, Jonathan Hunt on Syngene's annual performance and outlook for FY23

Syngene reported a 19% growth in revenue from operations for the entire year of FY22. Watch this video as our CEO and MD, Jonathan Hunt, speaks about Syngene’s performance, the outlook for FY 23, Syngene’s contribution in the fight against the pandemic, focus areas for the coming year, and more.

Play Video

To watch the on-demand video, please submit your work details.

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details